Andrew Althouse's guest appearances

Andrew Althouse

Interviews

The Accad and Koka Report

Elon Musk

Sally Satel

Terence Kealey

Robert Yeh

Adam Mortara

Damian Carabello

Martha Gulati

Geoffrey Rose

Paul Fine

Manny Sethi

George Delgado

Richard Menger

Tracy Høeg

Daniel Jafari

Paul Offit

OwlTail

Our guest is Andrew Althouse, statistician at the Center for Clinical Trials and Data coordination in Pittsburgh. He holds an undergraduate degree in Statistics and a PhD in Epidemiology from the University of Pittsburgh. His main area of interest is the design of randomized control trials. He discusses adaptive randomized control trials, and dissects the recent news of the positive Remdesivir trial.

Our guest is Andrew Althouse, statistician at the Center for Clinical Trials and Data coordination in Pittsburgh. He holds an undergraduate degree in Statistics and a PhD in Epidemiology from the University of Pittsburgh. His main area of interest is the design of randomized control trials. He discusses adaptive randomized control trials, and dissects the recent news of the positive Remdesivir trial.

Andrew Althouse on Clinical Trial Design and Remdesivir

Our guest is Andrew Althouse, statistician at the Center for Clinical Trials and Data coordination in Pittsburgh. He holds an undergraduate degree in Statistics and a PhD in Epidemiology from the University of Pittsburgh. His main area of interest is the design of randomized control trials. He discusses adaptive randomized control trials, and dissects the recent news of the positive Remdesivir trial.GUEST:Andrew Althouse: Twitter and professional pageWATCH ON YOUTUBE:Watch the episode on our YouTube channelSUPPORT THE SHOWMake a small donation on our Patreon page on and join our discussion group or receive a free book.

Our guest is Andrew Althouse, statistician at the Center for Clinical Trials and Data coordination in Pittsburgh. He holds an undergraduate degree in Statistics and a PhD in Epidemiology from the University of Pittsburgh. His main area of interest is the design of randomized control trials. He discusses adaptive randomized control trials, and dissects the recent news of the positive Remdesivir trial.GUEST:Andrew Althouse: <a href="https://twitter.com/ADAlthousePhD?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor" rel="nofollow" target="_blank">Twitter</a> and <a href="https://profiles.dom.pitt.edu/faculty_info.aspx/Althouse6848" rel="nofollow" target="_blank">professional page</a>WATCH ON YOUTUBE:<a href="https://youtu.be/bSNW9NFvzA8" rel="nofollow" target="_blank">Watch the episode</a> on our YouTube channelSUPPORT THE SHOW<a href="https://www.patreon.com/accadandkoka" rel="nofollow" target="_blank">Make a small donation</a> on our Patreon page on and join our discussion group or receive a free book.

Ep. 123 Andrew Althouse on Clinical Trial Design and Remdesivir